← Every company
Novartis AG Patents
What Novartis AG has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
NVS on carbonthat →Filings on file
59
Granted
2
Still pending
57
Filed under
2 names
59 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIESA61K 39/395, C07K 16/244, A61K2039/505, C07K 16/24, C07K2317/14, C07K2317/21, C07K2317/24, C07K2317/40, C07K2317/565, C07K2317/76Filed as Novartis AG2026-06-23Markus HEITZMANN | pending |
| TREATMENT OF AUTOIMMUNE DISORDERS USING CHIMERIC ANTIGEN RECEPTOR THERAPYA61K 40/31, A61K 40/11, A61P 37/00, A61P 37/02, A61P 37/06, A61K2239/10, A61K2239/38, A61K 40/13, A61K 40/15, A61K 40/4211, A61K 40/50, A61K 31/7088, A61K 35/17, A61K 45/06, A61K2039/545, A61K2039/577, A61K2300/00, C07K 14/7051, C07K 16/2803, C07K2317/622, C12N 5/0635, C12N 5/0636, C12N2501/2315, C12N2501/515Filed as Novartis AG2026-06-11Bambang Adiwijaya | pending |
| SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDSC07D 257/02Filed as NOVARTIS AG2026-05-29Fritz ANDREAE | pending |
| REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMABA61K 9/00, C07K 16/2887, A61P 25/28, A61P 37/06, A61K 9/0019, A61K 39/395, A61K2039/505, A61K2039/54, A61K2039/545, C07K 16/28, C07K2317/21Filed as Novartis AG2026-05-14Erik Wallström | pending |
| HEPATITIS B ANTIBODIESFiled as Novartis AG2026-04-14Stefan EWERT | pending |
| PHARMACEUTICAL COMPOSITIONS COMPRISING MULTISPECIFIC ANTIBODIESA61K 39/39591, C07K 16/244, A61P 37/02, A61K 47/183, A61K 47/20, A61K 47/22, A61K 47/26, A61K2039/54, A61K2039/545, C07K2317/31, C07K2317/52, C07K2317/524, C07K2317/565, C07K2317/70, C07K2317/94Filed as NOVARTIS AG2026-03-30Shwetha IYER | pending |
| THERAPEUTIC ANTI-BAFF-R ANTIBODIESC07K 16/2878, A61K2039/545, C07K2317/21, C07K2317/41, C07K2317/52, C07K2317/565, C07K2317/72, C07K2317/732, C07K2317/76, C07K2317/92, C07K2317/94Filed as Novartis AG2026-03-23Claire BONAL | pending |
| MANUFACTURING SYSTEMS AND METHODSG21F 5/14, G21G 1/0005, G21F 5/125, A61J 3/00, G21F 5/015, G21F 5/02Filed as Novartis AG2026-03-19Graham Stewart Watters | pending |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGFC07H 21/00, C07K 16/22, A61P 7/10, A61P 27/02, A61P 37/00, A61P 17/06, A61P 27/06, A61P 9/10, A61P 43/00, A61P 33/14, A61P 19/02, A61P 15/00, A61P 15/08, A61P 29/00, A61P 35/00, A61K 39/395, A61K 39/39533, C07K 1/00, C07K 7/06, C07K 16/46, C07K2317/24, C07K2317/31, C07K2317/54, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/622, C07K2317/73, C07K2317/92, C12N 15/63Filed as Novartis AG2026-03-13Leonardo Borras | pending |
| TREM2 STABILIZING ANTIBODIESA61P 25/28, C07K 16/2803, A61P 37/02, A61P 25/00, A61P 25/16, A61P 29/00, A61K 39/3955, A61K 45/06, A61K2039/505, C07K2317/21, C07K2317/33, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/732, C07K2317/734, C07K2317/75, C07K2317/77, C07K2317/92, C07K2317/94, C07K2319/21, C12N 7/00, C12N 15/70, C12N 15/86, C12N2750/14143Filed as Novartis AG2026-03-11Verena BRAND | pending |
| REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF EPOXIDE IMPURITYA61K 9/1676, A61K 31/506, A61K 9/1617, A61K 9/1623, A61K 9/1635, A61K 9/1652, A61K 9/1682, A61K 9/2027, A61K 9/2077, A61K 9/4866, A61K 31/505Filed as Novartis AG2026-03-04André BITTERLICH | pending |
| MANUFACTURING SYSTEMS AND METHODSFiled as Novartis AG2026-02-12Graham Stewart Watters | pending |
| SODIUM CHANNEL BLOCKERSA61K 31/41, C07D 401/04, A61K 31/4439, C07D 257/04Filed as Novartis AG2026-02-09Robert Francis DAY | pending |
| REMIBRUTINIB DRUG SUBSTANCE AND DRUG PRODUCT SUBSTANTIALLY FREE OF EPOXIDE IMPURITYFiled as Novartis AG2026-02-02André BITTERLICH | pending |
| COMPOUNDS TARGETING DMPK FOR THE TREATMENT OF MYOTONIC DYSTROPHYA61K 47/542, C12N 15/1137, A61P 21/00, A61K 9/0019, A61K 31/712, A61K 31/713, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12N2310/3515, C12Y 207/11001, C12N2310/3521, C12N2310/3533Filed as Novartis AG2026-01-27Charles Robert ALLERSON | pending |
| TREATMENT OF ATOPIC DERMATITIS WITH MULTISPECIFIC ANTIBODIESC07K 16/244, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/31, C07K2317/52, C07K2317/76, C07K2317/94Filed as NOVARTIS AG2026-01-27Bo BANG | pending |
| TREATMENT OF FOOD ALLERGY USING ANTI-IGE ANTIBODIESC07K 16/4291, A61P 37/08, A61K 39/39566, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/92Filed as NOVARTIS AG2026-01-22Ivan Bottoli | pending |
| DOSING OF POLYOMAVIRUS NEUTRALIZING ANTIBODIESC07K 16/084, A61P 31/20, Y02A 50/30, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55, C07K2317/33, C07K2317/34, C07K2317/56, C07K2317/565, C07K2317/70, C07K2317/76, C07K2317/92, C07K2317/94, C12N2710/22022, G01N 33/56983, G01N2333/025, G01N2469/20Filed as Novartis AG2026-01-20Johanna R. ABEND | pending |
| CARBOXAMIDE DERIVATIVESA61K 31/422, C07D 413/12, C07D 413/14, A61P 19/04, A61P 27/06, A61P 19/00, A61P 43/00, A61P 9/00, A61P 11/06, A61P 19/02, A61P 9/12, A61P 13/02, A61P 13/12, A61P 17/02, A61P 11/00, A61P 19/08, A61P 29/00, A61P 9/14, A61P 13/00, A61K 31/4155, A61K2300/00Filed as Novartis AG2026-01-07Kamlesh Jagdis BALA | pending |
| USES OF OMALIZUMABA61K 9/08, A61K 39/395, A61K 39/39533, A61K 39/39566, A61M 5/2422, C07K 16/4291, A61P 27/02, A61P 37/00, A61P 11/06, A61P 17/00, A61P 37/08, A61P 11/02, A61P 17/04, A61K 9/00, A61K 9/0014, A61K 9/0019, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, A61M 5/178, A61M 5/20, A61M 5/2033, A61M 5/31, A61M 5/31513, A61M 5/31533, A61M 5/3243, A61M 5/329, A61M2005/3114, A61M2005/3139, A61M2005/3261, A61M2005/3264, A61M2205/0222, A61M2205/584, C07K 16/42, C07K2317/24, C07K2317/94Filed as Novartis AG2025-12-22Maria Chaikou | pending |
| Methods for Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (PCSK9) ReductionA61P 9/10, A61K 31/713, A61K 48/0066, A61P 3/06, C07H 21/02, C12N 15/1137, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3515, C12N2310/3521, C12N2310/3533, C12Y 304/21061Filed as Novartis AG2025-12-22David KALLEND | pending |
| COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSIONA61K 31/7125, C12N 15/113, A61P 25/14, A61P 9/10, A61P 25/28, A61P 25/00, A61P 25/08, A61P 25/16, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3341, C12N2310/341, C12N2310/346, C12N2320/30Filed as Novartis AG2025-12-22Manuela POLYDORO OFENGEIM | pending |
| TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKERA61K 31/397, A61P 37/00, A61P 21/00, A61P 25/28, A61P 29/00, A61K 9/2018, A61K 31/138, A61K 45/06, A61K2300/00Filed as Novartis AG2025-12-22Vassilios Aslanis | pending |
| Multi-Copy Gene Protein Expression SystemFiled as Novartis AG2025-12-22Clemens Achmüller | pending |
| FIBROBLAST GROWTH FACTOR-21-FC FUSION PROTEINSA61K 38/1825, C07K 14/50, A61P 3/08, A61P 43/00, A61P 1/16, A61P 3/00, A61P 1/18, A61P 3/04, A61P 3/06, A61P 3/10, A61P 1/00, A61K 38/00, A61K 45/06, C07K2319/30Filed as Novartis AG2025-12-19Brian R. BOETTCHER | pending |
| FAP TARGETING COMPOUNDS AND CONJUGATES THEREOFA61K 51/0455, C07D 401/12, A61P 35/00, A61K 51/0482, A61K2121/00, C07D 217/02Filed as NOVARTIS AG2025-12-17Vincent Jean François ACKER | pending |
| SODIUM CHANNEL BLOCKERSC07D 401/04, C07D 403/04, A61K 31/4439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/497, A61K 31/506, A61K 31/5377, C07B 59/002, C07D 401/14, C07D 403/14, C07D 405/14, C07D 407/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 495/04Filed as Novartis AG2025-12-16Aaron David DANILACK | pending |
| SODIUM CHANNEL BLOCKERSC07D 231/12, C07D 401/04, A61K 31/41, A61K 31/415, A61K 31/4439, A61K 31/444, A61K 31/5377, A61K 31/549, C07D 257/04, C07D 401/14, C07D 403/04, C07D 403/14, C07D 405/14, C07D 413/14, C07D 417/14Filed as Novartis AG2025-12-16Robert Francis DAY | pending |
| BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF PATIENTS WITH XIAP DEFICIENCY OR CDC42 MUTATIONSC07K 16/245, A61P 37/06, A61K 9/0019, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, C07K 16/244, C07K2317/31, C07K2317/522, C07K2317/524, C07K2317/565, C07K2317/76, C07K2317/92Filed as NOVARTIS AG2025-12-15Michael Keith BADMAN | pending |
| IMMUNE-ENHANCING RNAS FOR COMBINATION WITH CHIMERIC ANTIGEN RECEPTOR THERAPYA61K 31/4439, A61K 31/7088, A61P 35/00, A61K2039/876, A61K2239/57, A61K2239/38, A61K2239/39, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 39/39, A61K 39/39541, A61K 39/39558, A61K2039/505, A61K2039/55561, C07K 14/7051, C07K 16/2803, C07K 16/2818, C07K2317/622, C07K2319/03, C07K2319/33, C12N 15/117, C12N2310/17, C12N2310/3519, C12N2320/31, A61K2300/00Filed as Novartis AG2025-12-11Lexus R. Johnson | pending |
| HEPATITIS B ANTIBODIESA61P 31/20, C07K 16/082, A61P 1/16, A61P 35/00, A61K 39/42, A61K 45/06, A61K2039/505, C07K2317/21, C07K2317/24, C07K2317/30, C07K2317/33, C07K2317/55, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/76, C07K2317/92, G01N 33/5764, G01N2333/015, G01N2469/10, A61K2300/00Filed as Novartis AG2025-11-24Stefan Ewert | pending |
| DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USEC12N 15/1137, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/351, C12Y 304/21, C12Y 304/21061, C12N2310/3521, C12N2310/3533Filed as Novartis AG2025-11-24Stefan HAEMMIG | pending |
| AZA-QUINOLINE COMPOUNDS AND USES THEREOFA61K 31/506, C07D 471/04, A61P 35/00, A61K 31/444, A61K 31/5377, A61K 31/541, A61K 45/06, A61K2300/00Filed as NOVARTIS AG2025-11-21Ling LI | pending |
| Engineered Heterodimeric ProteinsC07K 16/244, C07K 16/2863, C07K 16/28, C07K 16/2803, C07K 16/32, C07K2317/31, C07K2317/50, C07K2317/522, C07K2317/55, C07K2317/60, C07K2317/66Filed as Novartis AG2025-11-14Regis CEBE | pending |
| PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIESA61K 9/0019, A61K 39/39591, A61P 17/06, A61P 37/02, A61P 37/06, A61P 19/02, A61P 19/08, A61P 29/00, A61K 9/08, A61K 47/10, A61K 47/18, A61K 47/20, A61K 47/26, A61K2039/505, C07K 16/244, C07K2317/21, C07K2317/94, H04L 5/0016, H04L 5/0023, H04L 5/0051Filed as NOVARTIS AG2025-11-14Susanne JOERG | 12741024 |
| METHODS OF TREATING METABOLIC DISORDERS WITH FGF21 VARIANTSA61K 38/18, A61K 38/1825, A61K 47/6811, A61P 5/50, A61P 9/10, A61P 1/16, A61P 3/00, A61P 9/00, A61P 3/04, A61P 3/06, A61P 3/10, A61P 9/12, A61K 9/08, A61K 9/19, A61K 45/06, A61K 47/18, A61K 47/26, A61K2300/00Filed as NOVARTIS AG2025-11-11Allison GOLDFINE | pending |
| GRIPPERA61M 5/3204Filed as Novartis AG2025-11-07Neil Cammish | pending |
| SELECTION VECTORS AND METHODS OF SELECTING EUKARYOTIC HOST CELLSFiled as Novartis AG2025-11-07Yehuda G. ASSARAF | pending |
| PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIESA61K 9/0019, A61K 39/39591, A61P 17/06, A61P 37/02, A61P 37/06, A61P 19/02, A61P 19/08, A61P 29/00, A61K 9/08, A61K 47/10, A61K 47/18, A61K 47/20, A61K 47/26, A61K2039/505, C07K 16/244, C07K2317/21, C07K2317/94, H04L 5/0016, H04L 5/0023, H04L 5/0051Filed as NOVARTIS AG2025-10-31Susanne JOERG | 12702711 |
| METHOD OF PRODUCTIONB65B 3/003, B65B 3/006, A61K 45/06, B65B 55/027, B65B 57/00, B65B 57/005, B65B 65/00, B65B2220/16, G21G 4/08Filed as Novartis AG2025-10-30Geert Vandenbossche | pending |
| CYCLIN-DEPENDENT KINASE INHIBITORSC07D 487/04, A61P 35/00, A61K 31/4545, A61K 31/519, A61K 31/55, C07D 471/04, C07D 519/00Filed as Novartis AG2025-10-29Xin CHEN | pending |
| Amino Pyrimidine DerivativesC07D 239/47, Y02P 20/55, A61P 35/02, A61P 29/00, A61P 35/00, A61K 31/505, A61K 31/506, A61K 31/513, C07D 401/10, C07D 401/12, C07D 401/14, C07D 403/12, C07D 405/12Filed as Novartis AG2025-10-17Daniela Angst | pending |
| MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONSA61K 39/395, C07K 16/2863, A61P 5/50, A61P 3/08, A61P 9/10, A61P 43/00, A61P 1/16, A61P 3/00, A61P 3/04, A61P 3/06, A61P 19/02, A61P 3/10, A61P 9/12, A61P 13/12, A61P 5/00, A61P 5/24, A61P 9/04, A61P 15/08, A61P 19/10, A61P 35/00, A61K 45/00, A61K2039/505, A61K2039/545, C07K2317/21, C07K2317/76Filed as Novartis AG2025-10-15Tania Silvia GARITO | pending |
| METHODS OF USING FACTOR B INHIBITORSA61K 31/454, A61P 7/06, A61K 9/0053Filed as Novartis AG2025-10-08Irina BALTCHEVA | pending |
| BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITORA61K 39/39558, A61P 35/00, A61K 31/7088, A61K2039/505, C07K 16/2809, C07K 16/2878, C07K2317/31, C07K2317/55, C07K2317/622, A61K2300/00Filed as Novartis AG2025-10-02Michael Daley | pending |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORSA61P 19/08, A61K 31/4427, C07D 401/14, C07D 405/14, A61P 19/00, Y02A 50/30, A61K 31/4439, A61K 31/4545, C07B2200/07, C07D 213/82, C07D 401/10, C07D 401/12, C07D 409/14, C07D 411/14, C07D 413/00, C07D 413/10, C07D 413/12, C07D 413/14, C07D 417/00, C07D 419/00, C07D 491/107, C07D 491/20Filed as NOVARTIS AG2025-10-01Luca ARISTA | pending |
| CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDEC07D 401/14, A61P 35/00, A61K 9/0053, A61K 9/20, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/2095, A61K 9/28, A61K 31/4439, C07B2200/13Filed as Novartis AG2025-09-24Stephanie Kay DODD | pending |
| PIPERIDINYL-METHYL-PURINE AMINE FUMARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONSC07D 473/34, A61P 35/02, A61P 9/12, A61P 35/00, A61K 31/52, C07B2200/13Filed as Novartis AG2025-09-23Terrence Joseph Connolly | pending |
| METHOD OF TREATING EARLY BREAST CANCER WITH RIBOCICLIB IN COMBINATION WITH AN AROMATASE INHIBITORA61K 31/4196, A61K 31/519, A61P 35/00, A61K 45/06, A61K2300/00Filed as Novartis AG2025-09-19Arunava CHAKRAVARTTY | pending |
| COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASEA61P 25/02, C12N 15/113, C12N 15/1138, A61P 25/28, A61K 31/7088, C07H 21/02, C07H 21/04, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/3515, C12N2320/11, C12N2320/30, C12N2320/32, C12N2310/3521, C12N2310/3533Filed as Novartis AG2025-09-17Charles ALLERSON | pending |
| ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIESC07K 16/4291, A61P 37/08, A61K 9/0019, A61K 9/08, A61K2039/505, A61K2039/545, C07K2317/24, C07K2317/76Filed as Novartis AG2025-09-17Ryan Patrick OWEN | pending |
| ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIESC07K 16/4291, A61P 37/08, A61K 9/0019, A61K 9/08, A61K2039/505, A61K2039/545, C07K2317/24, C07K2317/76Filed as Novartis AG2025-09-17Ryan Patrick OWEN | pending |
| USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCERA61K 51/0482, C07D 257/02, C07D 295/145, A61P 13/08, A61P 35/04, A61P 35/00, G01N 33/575, A61K 51/04, A61K 51/0402, A61K 51/044, A61K 51/0497, C07B 59/002, G01N 33/60Filed as NOVARTIS AG2025-09-11Matthias EDER | pending |
| ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDSA61P 31/12, C07D 471/04, A61P 31/22, A61K 31/4985Filed as Novartis AG2025-09-11Christopher BECKER | pending |
| USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCERA61K 51/0482, C07D 257/02, C07D 295/145, A61P 13/08, A61P 35/04, A61P 35/00, G01N 33/575, A61K 51/04, A61K 51/0402, A61K 51/044, A61K 51/0497, C07B 59/002, G01N 33/60Filed as NOVARTIS AG2025-09-11Matthias EDER | pending |
| USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCERA61K 51/0482, C07D 257/02, C07D 295/145, A61P 13/08, A61P 35/04, A61P 35/00, G01N 33/575, A61K 51/04, A61K 51/0402, A61K 51/044, A61K 51/0497, C07B 59/002, G01N 33/60Filed as NOVARTIS AG2025-09-11Matthias EDER | pending |
| PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOFA61K 51/0402, C07D 257/02, Y02P 20/55, A61P 35/04, A61P 35/00, A61K 51/0482, A61K 51/0497, C07B2200/05Filed as Novartis AG2025-09-11Donato Barbato | pending |
| ANTIBODIES TARGETING IL-31C07K 16/244, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/526, C07K2317/55, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/92, C07K2317/94Filed as NOVARTIS AG2025-09-10Regis CEBE | pending |
| PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFA61K 47/6889, A61K 47/6851, A61K 47/6803, A61P 35/00, G01N 33/5011Filed as NOVARTIS AG2025-09-10Matthew T. BURGER | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.